About the AuthorMy name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market.
My ProfileI am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!
About This BlogEye on FDA is published by Mark Senak of FleishmanHillard's Washington, D.C. office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
My Favorite Dogs
Monthly Archives: February 2006
Over the course of the next several days, I’m going to be writing on the many ways in which the new regulatory era is going to affect business as usual for bringing new products to market. Lesson 1 – The … Continue reading
For those working in or around the pharmaceutical or biologics industry, it is understood that the issues a product faces in coming to market are not confined to the FDA. In other words, while the FDA focus is strictly on … Continue reading
Are drugs suddenly riskier or is the FDA suddenly more vigilant? Questions about the agency’s efficacy in protecting public health began to increase a few years back, when the ephedra issue presented itself and many critics thought that the agency … Continue reading
According to FDA regulations, one cannot state a claim that one’s drug or biologic is superior to another unless there has been a head to head study demonstrating that superiority. That regulatory reality can be frustrating to communications professionals who … Continue reading